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Мета. Обґрунтування методології класифікації ліко-пов’язаних помилок (Л-ПП) під час роздрібної реа-
лізації лікарських засобів в Україні 
Матеріали та методи. За допомогою системно-аналітичного, статистичного, порівняльного методів 
аналізу, а також описового та абстрактного модулювання й узагальнення нами було досліджено вітчи-
зняні та іноземні наукові публікації та нормативно-правова база. 
Результати. Аналіз сучасного стану вітчизняної системи фармаконгляду, показав, що нею передбачено 
повідомлення про випадки появи побічних реакцій ЛЗ, відсутності їх ефективності, однак відсутні кате-
горії, які б характеризували помилки, пов’язані з ЛЗ, зокрема під час роздрібної реалізації в аптечних за-
кладах та самолікуванні. Разом з тим, незважаючи на відсутність єдиної уніфікованої класифікації Л-
ПП, можна виділити основні категорії Л-ПП та згрупувати їх за етапами виникнення: Л-ПП, що трап-
ляються під час призначення ЛЗ, застосування ЛЗ під час стаціонарного лікування, та при відпуску ЛЗ 
фармацевтичним працівником. За результатами порівняльного аналізу міжнародних систем класифіка-
цій та моніторингу Л-ПП визначено, що більшість з них включають категорії Л-ПП пов’язані з дозою, 
умовами та тривалістю прийому ЛЗ, відповідності призначень ЛЗ пацієнтові, дотримання пацієнтом 
призначеної / рекомендованої фармакотерапії та є адаптованими відповідно до умов розвитку галузі 
охорони здоров’я різних країн. 
Висновки. Узагальнено підходи до класифікації ліко-пов’язаних помилок та обґрунтовано з урахування 
загальносвітових та вітчизняних тенденцій розвитку фармацевтичного сектору галузі охорони здоров’я 
класифікаційну модель Л-ПП, що може застосовуватися під час роздрібної реалізації ЛЗ в Україні. За-
пропонована методологія класифікації Л-ПП під час роздрібної реалізації ЛЗ включає 44 категорії поми-
лок, які в залежності від етапу надання фармацевтичної допомоги розділені на три рівні: помилки під 
час вибору безрецептурного ЛЗ у ході консультування фармацевтичним працівника, помилки під час від-
пуску ЛЗ фармацевтичним працівником та помилки на етапі застосування ЛЗ пацієнтом 
Ключові слова: ліко-пов’язана помилка, фармаконагляд, методологія класифікації, фармацевтична до-
помога 
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1. Introduction 
The current state of development of the pharma-
ceutical sector of health care, the increase in the number 
of pharmacies and the nomenclature of drugs, the rapid 
increase in the pace of life of the population, the current 
socio-economic conditions and the policy of pharmaceu-
tical manufacturing companies have caused the problem 
of uncontrolled and irrational use of drugs. According to 
the World Health Organization (WHO), more than 50 % 
of all drugs in the world are prescribed, issued or re-
leased incorrectly. In this case, 50 % of consumers are 
mistaken in the method of taking their prescribed medi-
cation [1, 2]. 
According to the State Expert Centre of the Min-
istry of Health of Ukraine (SEC), almost 7.4 % of regis-
tered medicines cause adverse reactions recorded in the 
system of post-registration pharmaceutical surveillance, 
of which approximately 97 % are related [1, 3]. At the 
same time, there are tendencies regarding insufficient 
information on adverse effects of the use of drugs dur-
ing self-medication, uncontrolled use of drugs by pa-
tients, uncontrolled dispensing of prescription drugs by 
pharmacies, inadequate or unqualified pharmaceutical 
care, etc. 
The aim of the research. In view of the afore-
mentioned aim of our study was to substantiate the meth-
odology of classification of drug-related errors (D-RE) 
during the retail sale of medicines in Ukraine.  
 
2. Planning (methodology) of research  
In order to substantiate the D-RE classification 
methodology, we have identified the following stages of 
the study: 
• analysis of the domestic system of pharmaceuti-
cal supervision of Ukraine regarding aspects of monitor-
ing of adverse effects of the use of drugs; 
• study of international D-RE classification expe-
rience; 
• comparative analysis of major D-RE classifica-
tion and monitoring systems in international practice; 
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• development and substantiation of D-RE classi-
fication methodology during retail sales of drugs in 
Ukraine. 
 
3. Materials and methods 
With the help of system-analytical, statistical, 
comparative methods of analysis, as well as descriptive 
and abstract modulation and generalization, we investi-
gated domestic and foreign scientific publications on 
approaches to the D-RE classification, as well as the 
regulatory framework regulating the functioning of the 
pharmaceutical surveillance system in Ukraine.  
 
4. Result of the research 
By WHO definition, pharmaceutical surveillance 
(pharmacovigilance) is a scientific field and practice 
related to the detection, evaluation, understanding and 
prevention of adverse effects or any other problems re-
lated to drugs. Supervision of the safety of drugs in their 
medical application is one of the main directions in the 
implementation of national policies on drugs in all coun-
tries of the world. 
Pharmacovigilance in Ukraine is regulated by the 
order of the Ministry of Health of Ukraine No. 898 of 
December 27, 2006 “On approval of the Pharmacovigi-
lance Procedure”, according to which adverse effects of 
the use of medicines are also identified, namely a side 
reaction. It is defined as any unintentional and harmful 
reaction to drug, and its types as group, predicted, un-
foreseen, serious, non-serious, as well as the lack of 
effectiveness of drug - the absence of a favourable diag-
nostic, therapeutic or prophylactic effect of the drug on 
establishing the nature of the disease, its course, duration 
or correction of the condition or physiological functions 
of the human body according to the indications for use 
specified in the instructions for medical use [4].  
Domestic pharmacovigilance system introduces 
documented forms of reports on the adverse effects of the 
use of drugs, namely, Card notifications for providing 
the patient and / or his representative with information 
about adverse reactions to drugs, vaccines, tuberculin, 
and / or lack of effectiveness of drugs, and / or adverse 
event after immunization / tuberculin diagnostics (Ap-
pendix 2 in the version of the Ministry of Health Order # 
996 of 26.09.2016) and Card-report on adverse reaction 
of drug, vaccine, tuberculin and / or lack of effective-
ness of drug, and / for adverse events after immuniza-
tion / tuberculin (NPPI) (Appendix 6 to the wording of 
MoH № 996 of 26.09.2016) [5].  
In addition to these documented forms, the Auto-
mated Pharmacovigilance Information System (AISF) 
operates in Ukraine, which provides for the filling of 
card messages on an official website designed to support 
the process of monitoring adverse reactions or lack of 
efficacy of drugs in Ukraine [6]. In addition, information 
on the occurrence of a side effect or lack of effectiveness 
of drugs can be reported by filling in the appropriate 
forms on the website of the information-search system 
"State Register of Medicines", which is the development 
of the SEC of the Ministry of Health of Ukraine [7]. 
In the course of studying the domestic system of 
pharmacovigilance, we found that it provides information 
on such types of cases as adverse reaction, lack of effica-
cy of drugs, adverse event after immunization with a 
detailed description of the case of their manifestation. 
However, it is not necessary to indicate the reason that 
could potentially lead to such cases [5–7]. 
It should be noted that filling in the Message 
Cards is intended to provide a message from a health 
care provider and a patient or his representative. The 
AISF also includes notifications from the applicant 
(pharmaceutical manufacturing company), but there is no 
adaptation regarding errors that occur during the retail 
sale of drugs or during the self-medication phase [6]. 
At the same time, as international experience 
shows, adverse effects of the use of drugs on the patient 
are not always manifested as a side effect or lack of effi-
cacy of drugs, and are not necessarily the result of thera-
peutic action of drugs in humans. In recent years, the 
term "medication error", which is defined as "medica-
tion" or "drug-related error", "drug related problem", 
"drug therapy problem", etc., has been increasingly used 
in the world to describe the adverse effects of the treat-
ment of patients with pharmaceutical drugs. 
In the course of the study, we found that today 
there is no single system in the world for identifying and 
classifying related errors. The most common and imple-
mented by various countries at the national level is the 
definition proposed by the US National Coordinating 
Council for Reporting and Prevention (NCC MERP), in 
particular, a drug-related error - any phenomenon (avoid-
able occurrence) that occurred while using a medication 
under the control of a healthcare professional, patient, or 
consumer, and which could lead to the inappropriate use 
of the medication or cause harm to health patient [8]. 
International experience shows that different ap-
proaches to the classification and monitoring of health-
related errors are used in the healthcare industry. Com-
parative analysis of common systems such as Cipolle / 
Morley / Strand classification, Granada Consensus DRP 
Classification, NCC MERP, Pharmaceutical Care Net-
work Europe (PCNE) Classification V 8.03, Problem-
intervention documentation (PI-Doc), SHB-SEP classifi-
cation and Westerlund system presented in the Table 1. 
According to the research of different monitor-
ing systems for drug-related errors, it is determined 
that the error message can be made by different 
healthcare professionals, namely, doctors, nurses, 
clinical pharmacists, pharmaceutical workers of phar-
macy establishments, as well as patients who use the 
drug, or its representative. 
Most classification systems include categories re-
lated to dose, conditions and duration of medication 
administration, appropriateness of medication prescribing 
to the patient, compliance with prescribed / recommend-
ed pharmacotherapy by the patient. In addition, systems 
such as the Granada Consensus DRP Classification, 
Problem-Intervention Documentation (PI-Doc), the SHB-
SEP classification, and the Westerlund system have been 
developed by governmental authorities in the field of 
pharmacy or professional associations and include ele-
ments specific to their health care systems. In general, 
the study of different types and approaches to the classi-
fication of D-RE provides an opportunity to generalize 
the tendencies for their classification and define criteria 
(Fig. 1) [9].  
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Table 1 
Comparative analysis of major classification systems and monitoring of drug-related errors 
 
The name of the system 
Country, year of 
introduction 
Characteristics of the monitoring 
system 
Ability to report different sub-
jects on D-RE 
Hospital 
level 
Pharmacy 
level 
Patient 
level 
Cipolle/Morley/Strand 
classification 
USA; 1999 
The system is being implemented 
by US retail pharmacies to eval-
uate the work of pharmacies in 
providing pharmaceutical care. 
+   
Granada Consensus DRP 
Classification 
Spain, Portugal; 
1998 
The classification is based on 
negative clinical results by cate-
gory of indication, efficacy, 
drug, safety 
+ + + 
NCC MERP USA; 1996 
The D-RE classification is con-
ducted in 9 categories (A-I) ac-
cording to the severity of the 
effects of the use of drugs 
+  + 
Pharmaceutical Care Net-
work Europe (PCNE) Clas-
sification V 8.03 
Finland, Swit-
zerland, Nether-
lands, Sweden, 
Great Britain, 
Belgium, Aus-
tria; 
1999 
PCNE Classification constantly 
reviewed in line with changes in 
the health care system. The fol-
lowing components are included 
in the system: 
• problems (3 categories, which 
include 7 D-RE); 
• causes (8 categories 37 causes of 
D-RE); 
• interventions (4 categories and 16 
possible interventions that may stop 
D-RE); 
• deciding on intervention (3 cate-
gories and 10 D-RE intervention 
results); 
• D-RE status (7 categories of 
current D-RE status) 
+ + + 
Problem–intervention doc-
umentation (PI-Doc) 
Germany, 
Denmark; 1995 
The hierarchical system for PI-
Doc is designed with ease of use 
in a pharmacy facility and im-
plemented in most German 
pharmacy pharmaceutical infor-
mation systems. 
 + + 
SHB-SEP classification 
Netherlands; 
2003 
The system, which includes the 
D-RE categories both in terms of 
the patient and the level of phar-
macies, is implemented in phar-
macies and is regularly reviewed. 
 + + 
Westerlund system Sweden, 2001 
The classification is based on 
circumstances related to the use 
of drugs that actually or poten-
tially prevent the patient from 
obtaining the desired benefit of 
the drugs. 
 + + 
 
 
 
Taking into account the results of the review of the 
different D-RE classification systems and the tendencies 
characteristic of the domestic healthcare sector, in particu-
lar, the uncontrolled dispensing of prescription drugs, we 
have developed a classification model that can be applied 
during the retail sale of drugs in Ukraine (Table 2). 
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Fig. 1. Generalization of global trends for classification of drug-related errors by criteria 
 
 
 
Our methodology for classifying slightly drug-
related errors during the retail sale of drugs consists of  
29 categories of errors, which are divided into two levels 
depending on the stage of providing pharmaceutical 
assistance: errors in the choice of OTC drugs in the pro-
cess of pharmaceutical counselling and errors during the 
release of drugs by a pharmaceutical worker. 
It should also be noted that the error categories  
B 6.1 - B 6.5 and B 9 provide administrative liability 
under the Code of Administrative Offenses (Articles 42-
4, 167, 168-1, 170) [10]. However, in our opinion, giv-
en the current trends in the state and development of 
the pharmaceutical sector in the healthcare sector, it is 
important to include these categories in the classifica-
tion model at the initial stage of implementation of the 
monitoring system for drug-related errors. In the fu-
ture, the D-RE classification system may be revised in 
connection with the reform of the health care system 
and the new challenges facing pharmaceutical  
workers. 
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Table 2 
Methodology for classifying drug-related errors during the retail sale of medicines 
Error code Error stage The contents of the error 
А 1 
The choice of 
OTC drugs in 
the process of 
consulting by 
pharmaceutical 
worker 
Non-compliant drug as recommended by the prescriber / form / protocol 
А 2 Absence of indications in the patient for use of drugs 
А 3 Incorrect combination of drugs 
А 4 Inappropriate drug dosage form (for a specific patient) 
А 5 Improper duplication of therapeutic group or active ingredient 
А 6 Improper replacement of a drug appointed by a physician within one treatment 
group 
А 7.1 
Inappropriate 
dose 
Drug dose is overstated 
А 7.2 Drug dose is lowered 
А 7.3 The dosage regimen is overstated 
А 7.4 The dosage regimen is lowered 
А 7.5 Dosing instructions are incorrect, unclear or missing 
А 8 Inappropriate duration of use of drugs 
А 9 Lack of control of individual characteristics of the patient (pregnant women, chil-
dren, chronic patients, etc.) 
А 10 Recommendation of a prescription drug 
B 1 
Dispensing of a 
medication by a 
pharmaceutical 
worker 
Wrong release of drugs with inappropriate pharmacological action 
B 2 Release of inappropriate drugs within one pharmacotherapeutic group 
B 3 Release of incorrect dose of drugs 
B 4 Release of incorrect dosage form of drugs 
B 5 Release of medicines in the wrong amount 
B 6.1 
Release of poor 
quality drugs 
Drugs with expired shelf life  AO 
B 6.2 Absence of necessary marking of packaging of drugs AO 
B 6.3 Loss of marketable appearance of packaging AO 
B 6.4 A drug that has not been properly stored at the pharmacy AO 
B 6.5 Forged drugs AO 
B 7 The release of drug, which is in "quarantine" 
B 8.1 The absence of 
reservations on the 
use of drugs when 
they need 
No warning about interaction with other drugs 
B 8.2 No warning about the interaction of drugs with food and 
alcohol 
B 8.3 No warning regarding specific storage conditions of drugs 
В9 Release of prescription drugs without prior prescribing by a doctor AO 
 
5. Discussion of the results 
Considering the concept of responsible self-care 
[11], it is important to involve patients in the monitor-
ing and prevention of drug-related errors.  
Therefore, we have also substantiated the clas-
sification system of minor errors during the use of 
drugs by the patient, which includes 15 categories of 
errors (Table 3). 
 
Table 3 
A methodology for classifying drug-related errors in the concept of responsible self-care 
Error code Error stage The contents of the error 
С 1 
The use of 
drugs by the 
patient 
Do not use the patient's prescribed / recommended drugs 
С 2 Use of unnecessary drugs by the patient 
С 3.1 Incorrect dosage of 
drugs by the patient 
Administration of smaller dose of drugs 
С 3.2 Administration of larger dose of drugs 
С 4 Drug abuse (addictive) 
С 5 Inadequate duration of use of drugs (prescribed / recommended drug course not fully 
completed) 
С 6 Reception of concomitant drugs that affect the prescribed / recommended drugs 
С 7.1 
Incorrect mode of drug 
administration 
The dosage regimen is overstated 
С 7.2 The dosage regimen is lowered 
С 7.3 Inappropriate time of day 
С 7.4 Improper use before meals 
С 7.5 Other 
С 8 The use of drugs the wrong route of administration 
С 9 Inability to take the prescribed / recommended dosage form for a particular patient 
С 10 Other 
Scientific Journal «ScienceRise: Pharmaceutical Science»                                                                     №1 (23)2020 
 
9 
Thus, it can be argued that the presented classifi-
cation model will promote the rational, safe and effective 
use of drugs, both prescription and over-the-counter, in 
particular, reduce the number of cases of errors associat-
ed with the use of drugs by the patient, as well as identify 
a new role for the pharmaceutical worker in modern 
conditions providing pharmaceutical assistance in 
Ukraine. 
  
6. Conclusions 
We generalized approaches to classification of 
drug-related errors (D-RE) and substantiate of the classi-
fication model that can be applied during retail sales of 
drugs in Ukraine. 
The analysis of the functioning of the domestic 
pharmacovigilance system, which provides reports of 
occurrences of adverse drug reactions, lack of their effec-
tiveness, but no categories characterizing errors related to 
drugs, in particular during retail sales in pharmacies. 
Based on the comparative analysis of 7 major in-
ternational D-RE classification and monitoring systems, 
most of them include D-RE categories related to dose, 
conditions and duration of medication administration, 
compliance with the patient's prescribing, compliance 
with prescribed / recommended pharmacotherapy, and 
adapted to the conditions of development of the 
healthcare sector of different countries. 
It is established that today there is no single uni-
fied D-RE classification in the world. Taking into ac-
count the general trends, it is possible to distinguish 
errors that occur during the prescribing of drugs, the use 
of drugs during inpatient treatment, and when pharma-
ceutical worker dispense drugs. 
Based on the international experience and cur-
rent state of the national healthcare sector, and taking 
into account the concept of responsible self-medication, 
we have proposed a D-RE classification methodology 
for the retail sale of drugs, consisting of 44 error cate-
gories, which, depending on the stage of providing 
pharmaceutical assistance divided into three levels: 
errors in the selection of OTC drugs in the course of 
consulting by pharmacist, errors in the release of drugs 
by a pharmacist and errors at the stage of medication 
use by the patient. 
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